Clinical Trials Logo

Neovascularization, Pathologic clinical trials

View clinical trials related to Neovascularization, Pathologic.

Filter by:

NCT ID: NCT00813514 Withdrawn - Clinical trials for Age-Related Macular Degeneration

Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)?

Start date: January 2009
Phase: N/A
Study type: Interventional

Age related macular degeneration (AMD) is a multifactorial disease with a strong genetic component. Most importantly a genetic polymorphism in the gene encoding for the complement factor H (CFH) has been recently identified which is highly associated with an increased risk of developing AMD. This Tyr402His polymorphism located on chromosome 1q31 has been implicated to play a role in the development of the disease. For this purpose a total of 200 patients with wet AMD will be included in the study. As described in detail below, the current study aims to identify potentially non-responders to anti-VEGF therapy based on genetic analysis of VEGF polymorphism and complement factor H polymorphism.

NCT ID: NCT00618644 Withdrawn - Sickle Cell Anemia Clinical Trials

Ranibizumab for Neovascularization in Sickle Cell Retinopathy

Start date: January 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the ocular and non-ocular safety of a single dose of ranibizumab in treating neovascularization secondary to sickle cell retinopathy.

NCT ID: NCT00515684 Withdrawn - Clinical trials for Corneal Neovascularization

Corneal Thinning During Topical Bevacizumab Therapy

Start date: May 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether topical bevacizumab is safe or not when used in corneal neovascularization for long term period.

NCT ID: NCT00403156 Withdrawn - Clinical trials for Choroidal Neovascularization

Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Start date: November 2006
Phase: Phase 1
Study type: Interventional

The purpose of study is to determine if Lucentis combined with imatinib mesylate will help treatment in patients with newly diagnosed choroidal neovascularization.